Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.24.56 - insulysin

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Alzheimer Disease
A common genetic system for functional studies of pitrilysin and related M16A proteases.
A neglected modulator of insulin-degrading enzyme activity and conformation: The pH.
Accumulation of BRI2-BRICHOS ectodomain correlates with a decreased clearance of A? by insulin degrading enzyme (IDE) in Alzheimer's disease.
Altered expression of insulin-degrading enzyme and regulator of calcineurin in the rat intracerebral streptozotocin model and human apolipoprotein E-?4-associated Alzheimer's disease.
Amylin and its analogs: a friend or foe for the treatment of Alzheimer's disease?
Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo.
Association Between Polymorphisms of the Insulin-Degrading Enzyme Gene and Late-Onset Alzheimer Disease.
Association of insulin degrading enzyme gene polymorphisms with Alzheimer's disease: a meta-analysis.
Association studies between risk for late-onset Alzheimer's disease and variants in insulin degrading enzyme.
C allele of the rs2209972 single nucleotide polymorphism of the insulin degrading enzyme gene and Alzheimer's disease in type 2 diabetes, a case control study.
Catalytic Mechanism of Amyloid-? Peptide Degradation by Insulin Degrading Enzyme: Insights from Quantum Mechanics and Molecular Mechanics Style Møller-Plesset Second Order Perturbation Theory Calculation.
CDK5 Participates in Amyloid-? Production by Regulating PPAR? Phosphorylation in Primary Rat Hippocampal Neurons.
Characteristics of Insulin-degrading Enzyme in Alzheimer's Disease: A Meta-analysis.
Characterization of insulin-degrading enzyme-mediated cleavage of A? in distinct aggregation states.
Chia Seed Does Not Improve Cognitive Impairment in SAMP8 Mice Fed with High Fat Diet.
Cognitive and Disease-Modifying Effects of 11?-Hydroxysteroid Dehydrogenase Type 1 Inhibition in Male Tg2576 Mice, a Model of Alzheimer's Disease.
Combined risk effects of IDE and NEP gene variants on Alzheimer disease.
Concordant association of insulin degrading enzyme gene (IDE) variants with IDE mRNA, Abeta, and Alzheimer's disease.
Copper(I) and copper(II) inhibit A? peptides proteolysis by insulin-degrading enzyme differently: implications for metallostasis alteration in Alzheimer's disease.
Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families.
Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains.
Deletion of the fission yeast homologue of human insulinase reveals a TORC1-dependent pathway mediating resistance to proteotoxic stress.
Detergent resistant membrane-associated IDE in brain tissue and cultured cells: Relevance to Abeta and insulin degradation.
Development of monoclonal antibodies and quantitative ELISAs targeting insulin-degrading enzyme.
Drug Target Engagement Using Coupled Cellular Thermal Shift Assay-Acoustic Reverse-Phase Protein Array.
Enhanced Phospholipase A2 Group 3 Expression by Oxidative Stress Decreases the Insulin-Degrading Enzyme.
Enzyme kinetics from circular dichroism of insulin reveals mechanistic insights into the regulation of insulin-degrading enzyme.
Evidence for genetic linkage of Alzheimer's disease to chromosome 10q.
Functional human insulin-degrading enzyme can be expressed in bacteria.
Gain of PITRM1 peptidase in cortical neurons affords protection of mitochondrial and synaptic function in an advanced age mouse model of Alzheimer's disease.
Ginsenoside Rg1 Decreases A?1-42 Level by Upregulating PPAR? and IDE Expression in the Hippocampus of a Rat Model of Alzheimer's Disease.
GLP-1 receptor regulates cell growth through regulating IDE expression level in A?1-42-treated PC12 cells.
Identification and functional characterization of a putative IDE, C28F5.4 (ceIDE-1), in Caenorhabditis elegans: Implications for Alzheimer's disease.
Identification of the allosteric regulatory site of insulysin.
Impact of Insulin Degrading Enzyme and Neprilysin in Alzheimer's Disease Biology: Characterization of Putative Cognates for Therapeutic Applications.
Insulin degrading enzyme (IDE) genetic variants and risk of Alzheimer's disease: evidence of effect modification by apolipoprotein E (APOE).
Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease.
Insulin degrading enzyme and alpha-3 catenin polymorphisms in Italian patients with Alzheimer disease.
Insulin degrading enzyme contributes to the pathology in a mixed model of Type 2 diabetes and Alzheimer's disease: possible mechanisms of IDE in T2D and AD.
Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis.
Insulin-degrading enzyme and Alzheimer disease: a genetic association study in the Han Chinese.
Insulin-degrading enzyme antagonizes insulin-dependent tissue growth and Abeta-induced neurotoxicity in Drosophila.
Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention.
Insulin-degrading enzyme deficiency accelerates cerebrovascular amyloidosis in an animal model.
Insulin-degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques.
Insulin-Degrading Enzyme in the Fight against Alzheimer's Disease.
Insulin-degrading enzyme inhibition, a novel therapy for type 2 diabetes?
Insulin-degrading enzyme is exported via an unconventional protein secretion pathway.
Insulin-degrading enzyme is genetically associated with Alzheimer's disease in the Finnish population.
Insulin-degrading enzyme prevents ?-synuclein fibril formation in a nonproteolytical manner.
Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo.
Insulin-degrading enzyme secretion from astrocytes is mediated by an autophagy-based unconventional secretory pathway in Alzheimer disease.
Insulin-degrading enzyme, apolipoprotein E, and Alzheimer's disease.
Insulin-Degrading Enzyme: A Link between Alzheimer's and Type 2 Diabetes Mellitus.
Insulin-degrading enzyme: new therapeutic target for diabetes and Alzheimer's disease?
Insulysin hydrolyzes amyloid beta peptides to products that are neither neurotoxic nor deposit on amyloid plaques.
Insulysin: an allosteric enzyme as a target for Alzheimer's disease.
Lack of association of 5 SNPs in the vicinity of the insulin-degrading enzyme (IDE) gene with late-onset Alzheimer's disease.
Links between Alzheimer's disease and diabetes.
Meta-analysis of the insulin degrading enzyme polymorphisms and susceptibility to Alzheimer's disease.
Metformin Ameliorates A? Pathology by Insulin-Degrading Enzyme in a Transgenic Mouse Model of Alzheimer's Disease.
Molecular basis for the recognition and cleavages of IGF-II, TGF-alpha, and amylin by human insulin-degrading enzyme.
Multiple insulin degrading enzyme variants alter in vitro reporter gene expression.
Mutation screening of a haplotype block around the insulin degrading enzyme gene and association with Alzheimer's disease.
Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity.
No association between the insulin degrading enzyme gene and Alzheimer's disease in a Japanese population.
Non-covalent interaction of ubiquitin with insulin-degrading enzyme.
Optimization of Peptide hydroxamate inhibitors of insulin-degrading enzyme reveals marked substrate-selectivity.
Physiological effects of manipulating the level of insulin-degrading enzyme in insulin-producing cells of Drosophila.
Plaque-associated overexpression of insulin-degrading enzyme in the cerebral cortex of aged transgenic tg2576 mice with Alzheimer pathology.
Polymorphisms of insulin degrading enzyme gene are not associated with Alzheimer's disease.
Positive association between risk for late-onset Alzheimer disease and genetic variation in IDE.
PPARgamma transcriptionally regulates the expression of insulin-degrading enzyme in primary neurons.
Promoter polymorphisms which modulate insulin degrading enzyme expression may increase susceptibility to Alzheimer's disease.
Protective effect of Notoginsenoside R1 on an APP/PS1 mouse model of Alzheimer's disease by up-regulating insulin degrading enzyme and inhibiting A? accumulation.
QM/MM Simulations of Amyloid-? 42 Degradation by IDE in the Presence and Absence of ATP.
Redox regulation of insulin degradation by insulin-degrading enzyme.
Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele.
Regulatory feedback cycle of the insulin-degrading enzyme and the amyloid precursor protein intracellular domain: Implications for Alzheimer's disease.
Sequence variants of IDE are associated with the extent of beta-amyloid deposition in the Alzheimer's disease brain.
Sequence variation in the proximity of IDE may impact age at onset of both Parkinson disease and Alzheimer disease.
Small-molecule activators of insulin-degrading enzyme discovered through high-throughput compound screening.
Somatostatin: a novel substrate and a modulator of insulin-degrading enzyme activity.
Statins induce insulin-degrading enzyme secretion from astrocytes via an autophagy-based unconventional secretory pathway.
Structure based discovery of small molecules to regulate the activity of human insulin degrading enzyme.
Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE.
Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease.
The Association Between Small Vessel Infarcts and the Activities of Amyloid-? Peptide Degrading Proteases in Apolipoprotein E4 AlleleCarriers.
The association between two single nucleotide polymorphisms within the insulin-degrading enzyme gene and Alzheimer's disease in a Chinese Han population.
The catalytic domain of insulin-degrading enzyme forms a denaturant-resistant complex with amyloid beta peptide: implications for Alzheimer disease pathogenesis.
The core sequence of PIF competes for insulin/amyloid ? in insulin degrading enzyme: potential treatment for Alzheimer's disease.
The extracellular matrix enriched with membrane metalloendopeptidase and insulin-degrading enzyme suppresses the deposition of amyloid-beta peptide in Alzheimer's disease cell models.
The irreversible binding of amyloid peptide substrates to insulin-degrading enzyme: a biological perspective.
The metalloendopeptidase gene Pitrm1 is regulated by hedgehog signaling in the developing mouse limb and is expressed in muscle progenitors.
The role of insulin, insulin growth factor, and insulin-degrading enzyme in brain aging and Alzheimer's disease.
Toward Allosterically Increased Catalytic Activity of Insulin-Degrading Enzyme against Amyloid Peptides.
Ubiquitin is a novel substrate for human insulin-degrading enzyme.
[Cerebral proteolysis of amiloid-b peptide: relevance of insulin-degrading enzyme in Alzheimer's disease]
[Effect of tongluo xingnao effervescent tablet on learning and memory of AD rats and expression of insulin-degrading enzyme in hippocampus].
[Kidney-reinforcing and Governor Vessel-regulating EA Intervention May Improve Learningmemory Possibly by Suppressing Formation of Senile Plaques in Hippocampus in APP/PS 1 Double Transgenic Alzheimer's Disease Mice].
Amyloidosis
Insulin-degrading enzyme deficiency accelerates cerebrovascular amyloidosis in an animal model.
Atherosclerosis
Insulin-degrading enzyme deficiency in bone marrow cells increases atherosclerosis in LDL receptor-deficient mice.
Brain Infarction
The Association Between Small Vessel Infarcts and the Activities of Amyloid-? Peptide Degrading Proteases in Apolipoprotein E4 AlleleCarriers.
Brain Ischemia
Pyrrolidine dithiocarbamate attenuates brain A? increase and improves long-term neurological outcome in rats after transient focal brain ischemia.
Carcinoma
Complex formation between metabolic enzymes in tumor cells: Unfolding the MDR1-IDE paradigm.
Carcinoma, Hepatocellular
Association of insulin-degrading enzyme with a 70 kDa cytosolic protein in hepatoma cells.
Dexamethasone inhibits insulin binding to insulin-degrading enzyme and cytosolic insulin-binding protein p82.
Identification of insulin-degrading enzyme on the surface of cultured human lymphocytes, rat hepatoma cells, and primary cultures of rat hepatocytes.
In vivo association of [125I]-insulin with a cytosolic insulin-degrading enzyme: detection by covalent cross-linking and immunoprecipitation with a monoclonal antibody.
Inhibition of insulin-degrading enzyme increases translocation of insulin to the nucleus in H35 rat hepatoma cells: evidence of a cytosolic pathway.
Cardiovascular Diseases
Effect of the Interplay Between Genetic and Behavioral Risks on Survival After Age 75.
Cerebellar Ataxia
Loss of function of the mitochondrial peptidase PITRM1 induces proteotoxic stress and Alzheimer's disease-like pathology in human cerebral organoids.
Cerebral Amyloid Angiopathy
Insulin-degrading enzyme in brain microvessels: proteolysis of amyloid {beta} vasculotropic variants and reduced activity in cerebral amyloid angiopathy.
Memantine, a Noncompetitive N-Methyl-D-Aspartate Receptor Antagonist, Attenuates Cerebral Amyloid Angiopathy by Increasing Insulin-Degrading Enzyme Expression.
Metformin attenuates vascular pathology by increasing expression of insulin-degrading enzyme in a mixed model of cerebral amyloid angiopathy and type 2 diabetes mellitus.
Chickenpox
Binding varicella zoster virus: an underestimated facet of insulin-degrading enzyme´s implication for Alzheimer´s disease pathology?
Development of monoclonal antibodies and quantitative ELISAs targeting insulin-degrading enzyme.
Insulin degrading enzyme binds to the nonglycosylated precursor of varicella zoster virus gE protein found in the endoplasmic reticulum.
Colonic Neoplasms
Immunohistochemical localization of insulin-degrading enzyme along the rat intestine, in the human colon adenocarcinoma cell line (Caco-2), and in human ileum.
Insulin-degrading enzyme in a human colon adenocarcinoma cell line (Caco-2).
Dementia
Accumulation of BRI2-BRICHOS ectodomain correlates with a decreased clearance of A? by insulin degrading enzyme (IDE) in Alzheimer's disease.
Differential degradation of amyloid beta genetic variants associated with hereditary dementia or stroke by insulin-degrading enzyme.
IDE Gene Polymorphism Influences on BPSD in Mild Dementia of Alzheimer's Type.
Insulin-degrading enzyme degrades amyloid peptides associated with British and Danish familial dementia.
Insulin-degrading enzyme haplotypes affect insulin levels but not dementia risk.
Machine Learning and Molecular Dynamics Based Insights into Mode of Actions of Insulin Degrading Enzyme Modulators.
Transducible P11-CNTF rescues the learning and memory impairments induced by amyloid-beta peptide in mice.
[Effect of tongluo xingnao effervescent tablet on learning and memory of AD rats and expression of insulin-degrading enzyme in hippocampus].
Dementia, Vascular
[Effect of rehabilitation training on insulin-resistance and hippocampus amyloid-beta peptide in rats with vascular dementia].
Diabetes Mellitus
Development of monoclonal antibodies and quantitative ELISAs targeting insulin-degrading enzyme.
Han ethnicity-specific type 2 diabetic treatment from traditional Chinese medicine?
Insulin-degrading enzyme antagonizes insulin-dependent tissue growth and Abeta-induced neurotoxicity in Drosophila.
Insulin-degrading enzyme is exported via an unconventional protein secretion pathway.
Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo.
Insulin-Degrading Enzyme: A Link between Alzheimer's and Type 2 Diabetes Mellitus.
Interleukin-6 increases the expression and activity of insulin-degrading enzyme.
Metformin attenuates vascular pathology by increasing expression of insulin-degrading enzyme in a mixed model of cerebral amyloid angiopathy and type 2 diabetes mellitus.
PPARgamma transcriptionally regulates the expression of insulin-degrading enzyme in primary neurons.
Redox regulation of insulin degradation by insulin-degrading enzyme.
Structure based discovery of small molecules to regulate the activity of human insulin degrading enzyme.
Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus.
Diabetes Mellitus, Type 2
A neglected modulator of insulin-degrading enzyme activity and conformation: The pH.
Association and haplotype analysis of the insulin-degrading enzyme (IDE) gene, a strong positional and biological candidate for type 2 diabetes susceptibility.
Association of polymorphisms in the insulin-degrading enzyme gene with type 2 diabetes in the Korean population.
C allele of the rs2209972 single nucleotide polymorphism of the insulin degrading enzyme gene and Alzheimer's disease in type 2 diabetes, a case control study.
Development of monoclonal antibodies and quantitative ELISAs targeting insulin-degrading enzyme.
Ensemble cryoEM elucidates the mechanism of insulin capture and degradation by human insulin degrading enzyme.
Enzyme kinetics from circular dichroism of insulin reveals mechanistic insights into the regulation of insulin-degrading enzyme.
FADD Phosphorylation Modulates Blood Glucose Levels by Decreasing the Expression of Insulin-Degrading Enzyme.
GLP-1 receptor regulates cell growth through regulating IDE expression level in A?1-42-treated PC12 cells.
Han ethnicity-specific type 2 diabetic treatment from traditional Chinese medicine?
High-Density Haplotype Structure and Association Testing of the Insulin-Degrading Enzyme (IDE) Gene With Type 2 Diabetes in 4,206 People.
IDE (rs6583817) polymorphism and type 2 diabetes differentially modify executive function in older adults.
Insulin degrading enzyme contributes to the pathology in a mixed model of Type 2 diabetes and Alzheimer's disease: possible mechanisms of IDE in T2D and AD.
Insulin-degrading enzyme antagonizes insulin-dependent tissue growth and Abeta-induced neurotoxicity in Drosophila.
Insulin-degrading enzyme inhibition, a novel therapy for type 2 diabetes?
Insulin-degrading enzyme is exported via an unconventional protein secretion pathway.
Insulin-degrading enzyme prevents ?-synuclein fibril formation in a nonproteolytical manner.
Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo.
Insulin-Degrading Enzyme: A Link between Alzheimer's and Type 2 Diabetes Mellitus.
Insulin-degrading enzyme: new therapeutic target for diabetes and Alzheimer's disease?
Interleukin-6 increases the expression and activity of insulin-degrading enzyme.
Metformin attenuates vascular pathology by increasing expression of insulin-degrading enzyme in a mixed model of cerebral amyloid angiopathy and type 2 diabetes mellitus.
Pancreatic beta-cell-specific deletion of insulin-degrading enzyme leads to dysregulated insulin secretion and beta-cell functional immaturity.
Polymorphisms in the insulin-degrading enzyme gene are associated with type 2 diabetes in men from the NHLBI Framingham Heart Study.
Polymorphisms within insulin-degrading enzyme (IDE) gene determine insulin metabolism and risk of type 2 diabetes.
PPARgamma transcriptionally regulates the expression of insulin-degrading enzyme in primary neurons.
Quantitative trait loci near the insulin-degrading enzyme (IDE) gene contribute to variation in plasma insulin levels.
Redox regulation of insulin degradation by insulin-degrading enzyme.
Regulation of insulin degrading enzyme activity by obesity-associated factors and pioglitazone in liver of diet-induced obese mice.
Structure based discovery of small molecules to regulate the activity of human insulin degrading enzyme.
Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus.
Epilepsy
In-frame deletion in canine PITRM1 is associated with a severe early-onset epilepsy, mitochondrial dysfunction and neurodegeneration.
Glioma
Expression of IDE and PITRM1 genes in ERN1 knockdown U87 glioma cells: effect of hypoxia and glucose deprivation.
Glucose Intolerance
Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein.
Catalytic site inhibition of insulin-degrading enzyme by a small molecule induces glucose intolerance in mice.
Liver-specific ablation of insulin-degrading enzyme causes hepatic insulin resistance and glucose intolerance, without affecting insulin clearance in mice.
Granuloma
Severe insulin resistance associated with subcutaneous amyloid deposition.
Heart Failure
Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure.
Herpes Zoster
Binding varicella zoster virus: an underestimated facet of insulin-degrading enzyme´s implication for Alzheimer´s disease pathology?
Development of monoclonal antibodies and quantitative ELISAs targeting insulin-degrading enzyme.
Insulin degrading enzyme binds to the nonglycosylated precursor of varicella zoster virus gE protein found in the endoplasmic reticulum.
Hyperglycemia
Rat brain insulin degrading enzyme in insulin and thyroid hormones imbalances.
Type 2 Diabetes Mellitus and Alzheimer's Disease: from physiopathology to treatment implications.
Hyperinsulinism
Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein.
Hyperinsulinemia caused by dexamethasone treatment is associated with reduced insulin clearance and lower hepatic activity of insulin-degrading enzyme.
Nigella sativa Oil and Chromium Picolinate Ameliorate Fructose-Induced Hyperinsulinemia by Enhancing Insulin Signaling and Suppressing Insulin-Degrading Enzyme in Male Rats.
Rat brain insulin degrading enzyme in insulin and thyroid hormones imbalances.
Reduced Insulin Clearance and Insulin-Degrading Enzyme Activity Contribute to Hyperinsulinemia in African Americans.
[Dementia and diabetes: Casual or causal relationship?]
Hypertension
Angiotensin-converting enzyme as a potential target for treatment of Alzheimer's disease: inhibition or activation?
Effects of Hypertension and Anti-Hypertensive Treatment on Amyloid-? (A?) Plaque Load and A?-Synthesizing and A?-Degrading Enzymes in Frontal Cortex.
Hyperthyroidism
Rat brain insulin degrading enzyme in insulin and thyroid hormones imbalances.
Hypothyroidism
Rat brain insulin degrading enzyme in insulin and thyroid hormones imbalances.
Infections
The amino terminus of varicella-zoster virus (VZV) glycoprotein E is required for binding to insulin-degrading enzyme, a VZV receptor.
The insulin degrading enzyme binding domain of varicella-zoster virus (VZV) glycoprotein E is important for cell-to-cell spread and VZV infectivity, while a glycoprotein I binding domain is essential for infection.
Varicella-zoster virus glycoprotein E is a critical determinant of virulence in the SCID mouse-human model of neuropathogenesis.
Insulin Resistance
Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease.
Effect of pioglitazone on altered expression of A? metabolism-associated molecules in the brain of fructose-drinking rats, a rodent model of insulin resistance.
Links between Alzheimer's disease and diabetes.
Liver-specific ablation of insulin-degrading enzyme causes hepatic insulin resistance and glucose intolerance, without affecting insulin clearance in mice.
Modulation of Insulin Sensitivity by Insulin-Degrading Enzyme.
Reduced insulin clearance and lower insulin-degrading enzyme expression in the liver might contribute to the thrifty phenotype of protein-restricted mice.
Reduced insulin sensitivity and increased ?/? cell mass is associated with reduced hepatic insulin-degrading enzyme activity in pregnant rats.
Relationship between insulin-degrading enzyme activity and insulin sensitivity in cell model of insulin-resistance.
Therapeutic Strategies for Alzheimer's Disease in the View of Diabetes Mellitus.
[Dementia and diabetes: Casual or causal relationship?]
Insulinoma
An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures.
insulysin deficiency
Insulin-degrading enzyme deficiency accelerates cerebrovascular amyloidosis in an animal model.
Insulin-degrading enzyme deficiency in bone marrow cells increases atherosclerosis in LDL receptor-deficient mice.
Loss of function of the mitochondrial peptidase PITRM1 induces proteotoxic stress and Alzheimer's disease-like pathology in human cerebral organoids.
Role of PITRM1 in Mitochondrial Dysfunction and Neurodegeneration.
Intellectual Disability
Defective PITRM1 mitochondrial peptidase is associated with A? amyloidotic neurodegeneration.
Liver Cirrhosis
Insulin-degrading activity in experimental liver cirrhosis of the rat.
Metabolic Syndrome
Insulin-degrading enzyme higher in subjects with metabolic syndrome.
Variants in the insulin-degrading enzyme gene are associated with metabolic syndrome in Chinese elders.
Neoplasms
Adiponectin receptor fragmentation in mouse models of type 1 and type 2 diabetes.
Attenuation of Aluminum Chloride-Induced Neuroinflammation and Caspase Activation Through the AKT/GSK-3? Pathway by Hesperidin in Wistar Rats.
Autophagy-dependent secretion: mechanism, factors secreted, and disease implications.
Dendrobiumpolysaccharides attenuate cognitive impairment in senescence-accelerated mouse prone 8 mice via modulation of microglial activation.
Immunohistochemical evidence of ubiquitous distribution of the metalloendoprotease insulin-degrading enzyme (IDE; insulysin) in human non-malignant tissues and tumor cell lines.
Insulin supplementation attenuates cancer-induced cardiomyopathy and slows tumor disease progression.
Intracellular insulin in human tumors: examples and implications.
Isorhynchophylline ameliorates cognitive impairment via modulating amyloid pathology, tau hyperphosphorylation and neuroinflammation: Studies in a transgenic mouse model of Alzheimer's disease.
Lack of association between IDE genetic variability and Down's syndrome.
No major role for insulin-degrading enzyme in antigen presentation by MHC molecules.
One for all and all for one: RB defends the cell while IDE, PTEN and IGFBP-7 antagonize insulin and IGFs to protect RB.
Production of an antigenic peptide by insulin-degrading enzyme.
Neuroblastoma
Novel Platinum(II) compounds modulate insulin-degrading enzyme activity and induce cell death in neuroblastoma cells.
Regulation by retinoic acid of insulin-degrading enzyme and of a related endoprotease in human neuroblastoma cell lines.
Neurodegenerative Diseases
Age-associated neurodegeneration and oxidative damage to lipids, proteins and DNA.
Insulin-degrading enzyme: an ally against metabolic and neurodegenerative diseases.
Neuroinflammatory Diseases
Intranasal Losartan Decreases Perivascular Beta Amyloid, Inflammation, and the Decline of Neurogenesis in Hypertensive Rats.
Sodium orthovanadate improves learning and memory in intracerebroventricular-streptozotocin rat model of Alzheimer's disease through modulation of brain insulin resistance induced tau pathology.
Obesity
Dissecting the nutrigenomics, diabetes, and gastrointestinal disease interface: from risk assessment to health intervention.
High-Fat Diet Modulates Hepatic Amyloid ? and Cerebrosterol Metabolism in the Triple Transgenic Mouse Model of Alzheimer's Disease.
In vitro inhibition of insulin-degrading enzyme by long-chain fatty acids and their coenzyme A thioesters.
Interleukin-6 increases the expression and activity of insulin-degrading enzyme.
Ovarian Neoplasms
Expression of metalloprotease insulin-degrading enzyme insulysin in normal and malignant human tissues.
Parkinson Disease
6-Hydroxydopamine induces secretion of PARK7/DJ-1 via autophagy-based unconventional secretory pathway.
Parkinsonian Disorders
6-Hydroxydopamine induces secretion of PARK7/DJ-1 via autophagy-based unconventional secretory pathway.
Polycystic Ovary Syndrome
Association of genetic variants of insulin degrading enzyme with metabolic features in women with polycystic ovary syndrome.
Prediabetic State
Relationship Between Cognitive Functions and Insulin-degrading Enzyme in Individuals With Prediabetes.
Retinoblastoma
Intracellular insulin in human tumors: examples and implications.
Retinoblastoma protein co-purifies with proteasomal insulin-degrading enzyme: implications for cell proliferation control.
Spinocerebellar Ataxias
Defective PITRM1 mitochondrial peptidase is associated with A? amyloidotic neurodegeneration.
In-frame deletion in canine PITRM1 is associated with a severe early-onset epilepsy, mitochondrial dysfunction and neurodegeneration.
Stroke
Differential degradation of amyloid beta genetic variants associated with hereditary dementia or stroke by insulin-degrading enzyme.
Varicella Zoster Virus Infection
Development of monoclonal antibodies and quantitative ELISAs targeting insulin-degrading enzyme.
Virus Diseases
Development of monoclonal antibodies and quantitative ELISAs targeting insulin-degrading enzyme.
Insulin degrading enzyme is a cellular receptor mediating varicella-zoster virus infection and cell-to-cell spread.